Clinical trials for rare diseases
European Pharmaceutical Review
MARCH 28, 2024
FDA is expected to provide initial feedback on the data submitted by July 2024, with further data to be collected and analysed over the next two years. What is the main reason submission of the DVA qualification to FDA is significant for future clinical trials?
52 
Let's personalize your content